Etanercept (50mg per week, for 2 weeks) (DrugBank: Etanercept)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 271 | Ankylosing spondylitis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04077957 (ClinicalTrials.gov) | October 7, 2019 | 1/9/2019 | Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs | Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study | Ankylosing Spondylitis;Spondyloarthritis | Drug: Methotrexate;Drug: Sulfasalazine;Drug: Hydroxychloroquine;Drug: Etanercept (50mg per week, for 4 weeks);Drug: Etanercept (50mg per week, for 2 weeks);Drug: Etanercept (50mg per week) | Nanfang Hospital of Southern Medical University | NULL | Not yet recruiting | 18 Years | 50 Years | All | 100 | Phase 4 | China |